{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:56:07Z","timestamp":1772780167777,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":437,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","award":["MC_UU_00004\/03"],"award-info":[{"award-number":["MC_UU_00004\/03"]}],"id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003784","name":"Great Ormond Street Hospital for Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["53816"],"award-info":[{"award-number":["53816"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["1005245"],"award-info":[{"award-number":["1005245"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cct.2024.107540","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T20:11:41Z","timestamp":1713298301000},"page":"107540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["D3\/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15\u00a0years"],"prefix":"10.1016","volume":"142","author":[{"given":"Anna","family":"Turkova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cissy","family":"Kityo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeodata R.","family":"Kekitiinwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippa","family":"Musoke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avy","family":"Violari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebrahim","family":"Variava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moherndran","family":"Archary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim R.","family":"Cressey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suwalai","family":"Chalermpantmetagul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanokkorn","family":"Sawasdichai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradthana","family":"Ounchanum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suparat","family":"Kanjanavanit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakulrat","family":"Srirojana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ussanee","family":"Srirompotong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair","family":"Bamford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Epalza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e0udia","family":"Fortuny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Colbers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Nastouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moira J.","family":"Spyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazia","family":"Parkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iona","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret J.","family":"Thomason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashida A.","family":"Ferrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cct.2024.107540_bb0005","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cct.2024.107540_bb0010","series-title":"Proceedings of the 18th European AIDS Conference (EACS), London, UK","first-page":"27","article-title":"SOLAR 3D: A prospective study switching to DTG\/3TC from 3-or 4-drug ART for maintenance of viral suppression with historic M184V\/I mutation and prior virological failures: 48 week primary endpoint results","author":"Blick","year":"2021"},{"issue":"11","key":"10.1016\/j.cct.2024.107540_bb0015","doi-asserted-by":"crossref","first-page":"ofac610","DOI":"10.1093\/ofid\/ofac610","article-title":"Long-term evaluation of residual viremia in a clinical trial of dolutegravir plus lamivudine as maintenance treatment for participants with and without prior lamivudine resistance","volume":"9","author":"De Miguel Buckley","year":"2022","journal-title":"Open Forum Infect. Dis."},{"issue":"3","key":"10.1016\/j.cct.2024.107540_bb0020","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jac\/dky467","article-title":"Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)","volume":"74","author":"Joly","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.cct.2024.107540_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz056","article-title":"No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial","volume":"6","author":"Li","year":"2019","journal-title":"Open Forum Infect. Dis."},{"issue":"4","key":"10.1016\/j.cct.2024.107540_bb0030","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.cct.2024.107540_bb0035","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.cct.2024.107540_bb0040","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(21)00100-4","article-title":"Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial","volume":"8","author":"Rojas","year":"2021","journal-title":"Lancet HIV"},{"issue":"11","key":"10.1016\/j.cct.2024.107540_bb0045","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/cid\/cix1131","article-title":"Dolutegravir plus lamivudine maintains human immunodeficiency Virus-1 suppression through week 48 in a pilot randomized trial","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2024.107540_bb0050","series-title":"HIV Drug Therapy Glasgow 2022; October 23\u201326","article-title":"Impact of switch towards 3TC\/dolutegravir on the intact and total viral reservoir in the Rumba study. Abstract M042","author":"Blomme","year":"2022"},{"key":"10.1016\/j.cct.2024.107540_bb0055","series-title":"The 12th IAS Conference on HIV Science; July 23-26","article-title":"Prior M184V\/I and multiple prior virological failures have no impact on the efficacy of switching HIV+ adults to DTG\/3TC through 96Wks in SOLAR-3D. Abstract OAB0202","author":"Blick","year":"2023"},{"issue":"3","key":"10.1016\/j.cct.2024.107540_bb0060","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkaa479","article-title":"Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: week 96 results of ART-PRO pilot study","volume":"76","author":"Rial-Crestelo","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cct.2024.107540_bb0065","series-title":"HIV Drug Therapy Glasgow; October 5\u20138","article-title":"Switching to DTG\/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 Weeks (TANGO Study). Abstract O441","author":"van Wyk","year":"2020"},{"issue":"8","key":"10.1016\/j.cct.2024.107540_bb0070","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cct.2024.107540_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102779","article-title":"Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)","volume":"55","author":"De Miguel","year":"2020","journal-title":"EBioMedicine"},{"issue":"10167","key":"10.1016\/j.cct.2024.107540_bb0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cct.2024.107540_bb0085","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of Dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr. (1999)"},{"issue":"1","key":"10.1016\/j.cct.2024.107540_bb0090","doi-asserted-by":"crossref","first-page":"21678","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (pilot antiretroviral design with Dolutegravir LamivudinE) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J. Int. AIDS Soc."},{"issue":"1","key":"10.1016\/j.cct.2024.107540_bb0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"Aids"},{"key":"10.1016\/j.cct.2024.107540_bb0100","series-title":"The 12th IAS Conference on HIV Science; July 23-26","article-title":"Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing: Week 24 results of the randomized D2ARLING study. Abstract TUPEB02","author":"Cordova","year":"2023"},{"key":"10.1016\/j.cct.2024.107540_bb0105","series-title":"IAS Conference on HIV Pathogenesis Treatment and Prevention, July 23-26","article-title":"Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-na\u00efve patients: 96 week results of the PADDLE trial. Abstract MOPEB0287","author":"Figueroa","year":"2017"},{"key":"10.1016\/j.cct.2024.107540_bb0110","series-title":"The 11th IAS Conference; July 18\u201321","article-title":"Feasibility, efficacy, and safety of dolutegravir\/lamivudine (DTG\/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV (PLWH): 48-week results of the STAT study. Abstract PEB 182","author":"Rolle","year":"2021"},{"issue":"12","key":"10.1016\/j.cct.2024.107540_bb0115","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0000000000002979","article-title":"Dolutegravir\/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV","volume":"35","author":"Rolle","year":"2021","journal-title":"Aids"},{"issue":"11","key":"10.1016\/j.cct.2024.107540_bb0120","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/cid\/cix1083","article-title":"ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies\/mL","volume":"66","author":"Taiwo","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.cct.2024.107540_bb0125","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/QAD.0000000000002285","article-title":"Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients","volume":"33","author":"Radford","year":"2019","journal-title":"Aids"},{"key":"10.1016\/j.cct.2024.107540_bb0130","series-title":"International Workshop on HIV & Adolescence 2022; October 5\u20136","article-title":"Efficacy and Safety of the 2-Drug Regimen Dolutegravir\/Lamivudine (DTG\/3TC) in Antiretroviral Therapy (ART)-Naive Adolescents Living With HIV-1: DANCE Study Week 48 Results. Abstract 2","author":"Puthanakit","year":"2022"},{"key":"10.1016\/j.cct.2024.107540_bb0135","series-title":"15th International Workshop on HIV & Pediatrics. Brisbane, Australia; July 21-22","article-title":"Efficacy and safety of Dolutegravir\/lamivudine (DTG\/3TC) in Antiretroviral Therapy (ART)-Naive Adolescents Living with HIV-1: DANCE Study Week 96 Results. Abstract EPB0250","author":"Puthanakit","year":"2023"},{"key":"10.1016\/j.cct.2024.107540_bb0140","unstructured":"Stanford University. HIV Drug Resistance Database. NRTI Resistance Notes. October 25, 2022. n.d. Available: https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/NRTI\/."},{"key":"10.1016\/j.cct.2024.107540_bb0145","series-title":"HIV Drug Therapy Glasgow 2022; October 23\u201326","article-title":"Effectiveness of dolutegravir + lamivudine in real-world studies in people with HIV-1 with M184V\/I mutations: a systematic review and meta-analysis. Abstract P081","author":"Kabra","year":"2022"},{"key":"10.1016\/j.cct.2024.107540_bb0150","series-title":"IDWeek 2021; September 29\u2013October 3","article-title":"Effectiveness and Tolerability of DTG + 3TC in Clinical Practice: Evidence in PLHIV from Real-world Data. Abstract 898","author":"Evitt","year":"2021"},{"key":"10.1016\/j.cct.2024.107540_bb0155","series-title":"BHIVA Spring Conference 2022; April 20\u201322","article-title":"Effectiveness and tolerability of the 2-drug regimen dolutegravir plus lamivudine in people with HIV-1: a systematic literature review of real-world evidence from clinical practice. Abstract P023","author":"Letang","year":"2022"},{"key":"10.1016\/j.cct.2024.107540_bb0160","article-title":"Antiretroviral adherence for adolescents growing up with HIV: understanding real life, drug delivery and forgiveness","volume":"7","author":"Foster","year":"2020","journal-title":"Ther. Adv. Infect. Dis."},{"issue":"27","key":"10.1016\/j.cct.2024.107540_bb0165","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as first- or second-line treatment for HIV-1 infection in children","volume":"385","author":"Turkova","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2024.107540_bb0170","author":"The Columbia Lighthouse Project"},{"key":"10.1016\/j.cct.2024.107540_bb0175","unstructured":"European AIDS Clinical Society Panel and Penta HIV Guidelines Working Group. EACS\/Penta Guidelines. Version 11. July 2021. n.d. (Avaialble (in preparation)."},{"key":"10.1016\/j.cct.2024.107540_bb0180","author":"World Health Organization"},{"issue":"1","key":"10.1016\/j.cct.2024.107540_bb0185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/174.1.16","article-title":"Lamivudine in children with human immunodeficiency virus infection: a phase I\/II study. The National Cancer Institute pediatric branch-human immunodeficiency virus working group","volume":"174","author":"Lewis","year":"1996","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.cct.2024.107540_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196239","article-title":"Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): extended follow-up results of a randomised, open-label, non-inferiority trial","volume":"13","author":"Turkova","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cct.2024.107540_bb0195","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s13063-023-07586-5","article-title":"The smooth away from expected (SAFE) non-inferiority frontier: theory and implementation with an application to the D3 trial","volume":"24","author":"Quartagno","year":"2023","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.cct.2024.107540_bb0200","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.3390\/v15091811","article-title":"Sensitive HIV-1 DNA pol next-generation sequencing for the characterisation of archived antiretroviral drug resistance","volume":"15","author":"Botha","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.cct.2024.107540_bb0205","author":"World Health Organization"},{"key":"10.1016\/j.cct.2024.107540_bb0210","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. n.d. Available: https:\/\/rsc.tech-res.com\/docs\/default-source\/safety\/daidsgradingcorrecetedv21.pdf."},{"key":"10.1016\/j.cct.2024.107540_bb0215","author":"NIH Division of Microbiology and Infectious Diseases (DMID)"},{"key":"10.1016\/j.cct.2024.107540_bb0220","unstructured":"World Health Organization. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access. Recommendations for a Public Health Approach - 2010 Revision. July 13, 2010. n.d."},{"key":"10.1016\/j.cct.2024.107540_bb0225","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). n.d. https:\/\/www.meddra.org\/ Accessed 18 August 2023."},{"issue":"1","key":"10.1016\/j.cct.2024.107540_bb0230","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13063-022-06097-z","article-title":"Planning a method for covariate adjustment in individually randomised trials: a practical guide","volume":"23","author":"Morris","year":"2022","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.cct.2024.107540_bb0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12879-020-05672-6","volume":"21","author":"Moore","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.cct.2024.107540_bb0240","series-title":"CROI","article-title":"Adult dolutegravir 50mg tablets in children living with HIV weighing 20 to <25 kg (abstract 830)","author":"Bollen","year":"2018"},{"key":"10.1016\/j.cct.2024.107540_bb0245","unstructured":"H. Waalewijn, P. Bollen, C. Moore, et al. Pharmacokinetics of dolutegravir 5mg dispersible tablets in children weighing 6 to <20kg dosed using WHO weight bands. Abstract WEAB0401LB. 10th IAS Conference on HIV Science; July 21-24, 2019; Mexico City, Mexico. n.d. Available: http:\/\/programme.ias2019.org\/Abstract\/Abstract\/4782."},{"issue":"10","key":"10.1016\/j.cct.2024.107540_bb0250","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"Aids"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171442400123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171442400123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:25:16Z","timestamp":1762550716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171442400123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":50,"alternative-id":["S155171442400123X"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2024.107540","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D3\/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15\u00a0years","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2024.107540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107540"}}